40,427 results on '"Metastatic breast cancer"'
Search Results
2. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES)
3. OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
4. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
5. Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
6. Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE)
7. A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)
8. A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
9. A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA)
10. A Study of TAS-120 in Patients With Metastatic Breast Cancer
11. Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
12. STOP-HER2: Stopping Trastuzumab in HER2+ MBC
13. Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer (Amelia-1)
14. Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
15. Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
16. Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
17. Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
18. Onvansertib + Paclitaxel In TNBC
19. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
20. ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study (ELCIN)
21. Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
22. Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. (Pangeia-2)
23. Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
24. T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4)
25. HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3)
26. Measuring Oncological Value of Exercise and Statin (MOVES)
27. Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer (DP METABREAST)
28. Couples' QOL in Metastatic Breast Cancer (C-QOL)
29. Roll-over Study to Allow Continued Access to Ribociclib
30. Scalp Cooling in MBC
31. Telephone Support for Metastatic Breast Cancer Patients
32. Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)
33. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)
34. Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer (ACCESS)
35. Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
36. Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
37. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)
38. Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
39. DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
40. BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
41. Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)
42. AR and ER Imaging in Metastatic Breast Cancer
43. Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites
44. Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
45. A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
46. Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)
47. A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
48. A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
49. Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer (EDC)
50. HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada (HER-TEMPO)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.